基本介紹
- 中文名：陳樞青
- 國籍：中國
- 民族：漢族
- 職業：浙江大學藥學院黨委副書記
研究方向,學歷背景,國外學習與研究,專訪信息,社會兼職,工作經歷,主要榮譽,獲獎情況,主要學術成果,主要專著、教材,主要論文,
研究方向
藥物代謝酶類及其在外來物代謝中的作用研究
生化藥物和基因工程新藥的開發研究
新藥篩選的分子模型研究
學歷背景
國外學習與研究
1993.12-1995.8 美國肯塔基大學藥學院訪問學者
2001.1-2002.1 美國康乃爾大學分子生物學系 博士後
專訪信息
專訪浙大陳樞青教授：精準醫療僅僅是測序嗎？
社會兼職
中國藥學會生物技術藥物專業委員會委員、浙江省藥學會生物藥物專業委員會主任委員、浙江省生物化學與分子生物學學會理事長、《中國現代套用藥學》雜誌編委和《Medical Science Monitor》雜誌國際編委。
工作經歷
1983.8-1985.8 浙江省餘姚丈亭衛生院 藥師
1985.9-1993.12 浙江醫科大學生物化學教研室 碩士研究生,助教, 講師
1993.12-1995.8 美國肯塔基大學藥學院 訪問學者
1995.8-1999.12 浙江大學醫學院生物化學教研室副教授，副主任
1998.8-2003.3 寧波大學醫學院 副院長，教授
2001.1-2002.1 美國康乃爾大學分子生物學系 博士後
2003.4-現在 浙江大學藥學院 教授，博士生導師
主要榮譽
浙江省高校中青年學科帶頭人、浙江省“新世紀151人才工程”第二層次人選，寧波市有突出貢獻專家。
獲獎情況
作為第一負責人獲得浙江省科技進步獎二等獎1次，三等獎2次。
主要學術成果
主要專著、教材
2.厲朝龍主編，楊歧生，陳樞青副主編. 《生物化學與分子生物學》. 中國醫藥科技出版社，2001，北京
3.陳樞青. 用藥與遺傳. 《醫學遺傳學》。張鹹寧主編，科學出版社，2002，北京.
4.陳樞青。 第11章 核酸代謝與蛋白質生物合成、第12章代謝和代謝調控總論 in 衛生部規劃教材《生物化學》第五版（供藥學類專業用）。吳梧桐主編。人民衛生出版社 2003年。
7.陳樞青。 第3章 基因工程製藥，衛生部“十一五”規劃教材《生物技術製藥》（供藥學類專業用）。周佩主編。人民衛生出版社 2007年
8.陳樞青。 第12章核酸與核苷酸代謝、第13章 代謝和代謝調控總論 、第14章 DNA的複製與修復、第15章 轉錄與基因表達調控、第16章 蛋白質的生物合成， 衛生部規劃教材《生物化學》第六版（供藥學類專業用）。吳梧桐主編。人民衛生出版社 2007年
主要論文
（其中近30篇被SCI或EI收錄）
1. Yingqiu Pan; Ding Ding; Danxi Li, Shuqing Chen. Expression and Bioactivity Analysis of Staphylococcal Enterotoxin M and N. Protein Expression and Purification. 2007; 56(2): 286-292
2. Spinola M, Falvella FS, Galvan A, Pignatiello C, Leoni VP, Pastorino U, Paroni R, Chen S, Skaug V, Haugen A, Dragani TA. Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients' survival. Lung Cancer. 2007; 55(3): 271-277
3. Chunna Yu, Su Zeng, and Shuqing Chen. In vitro evaluation for induction of traditional Chinese medicines on CYP3A4. DRUG METABOLISM REVIEWS 38: 138-138 Suppl. 3 2006
4. Shenggu Xie, Yakun Chen, Shuqing Chen and Su Zeng. Glucuronidation of flavonoids by human UGT1A3, UGT1A9 and structure-activity relationships. DRUG METABOLISM REVIEWS 38: 129-129 Suppl. 3 2006
5. Yakun Chen, Shuqing Chen, Xin Li, Xiewei Wang, and Su Zeng. Genetic Variants of Human UGT1A3: Functional Characterization and Frequency Distribution in a Chinese Han Population. Drug Metabolism and Disposition. 2006; May 31; 34:1-6
6. Mingliang Wu, Shuqing Chen, Xiaohong Wu. Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in chinese cancer patients. Medical Science Monitor. 2006, 12(5): 174-178.
7.Xue Qiao, Sun Hong-ying, Ying Yue-bin, Chen Shu-qing. Switch of regulatory domains of P-protein and T-protein from E. coli. Chinese Journal of Biochemistry and Molecular Biology. 2006, 22(4): 296-300.
8.Y.K. Chen, S.Q. Chen, X. Li, S. Zeng. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica. 2005; 35(10-11): 943-54.
9.Su Zeng, Shuqing Chen, Changxiao Liu. Introduction to 2005 Hangzhou International Conference on Drug Metabolism. Asian Journal of Drug Metabolism and Pharmacokinetics. 2005; 5(4): 243-50.
10.Ya-Kun Chen, Xin Li, Shu-Qing Chen, Su Zeng. Heterologous expression of active human uridine diphosphate glucuronosyltransferase 1A3 in Chinese hamster lung cells. World Journal of Gastroenterology. 2005；11(1):118-21.
11.Ming Rong Qian, Shu Qing Chen, Xin Li, Su Zeng. Cloning of human UGT1A4 cDNA and its expression in Bac-to-Bac system. Biochemical and Biophysical Research Communications. 2004; 319: 386-92
12.Weixing Shi, Shuqing Chen. Study on frequencies of poor metabolizers of cytochrome P450 2C19in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World Journal of Gastroenterology. 2004; 10(13): 1961-3.
13.Shuqing Chen, Sarah Vincent, David B. Wilson and Bruce Ganem. Mapping of Chorismate Mutase and Prephenate Dehydrogenase Domains in the Escherichia coli T-protein. European Journal of Biochemistry. 2003; 270(4): 757-63
14.Sarah Vincent, Shuqing Chen, David B. Wilson and Bruce Ganem. Probing the overlap of chorismate mutase and prephenate dehydrogenase sites in the Escherichia coli T-protein: a dehydrogenase-selective inhibitor. Bioorganic & Medicinal Chemistry Letters, 2002; 12(6): 929-931
15.Husain A, Chen S, Wilson DB, Ganem B, "A Selective Inhibitor of Prephenate Dehydratase," Bioorganic & Medicinal Chemistry Letters. 2001; 11(18): 2485-2488
16.TW Yao, S Zeng, TW Wang, SQ Chen. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. Biomedical chromatography 2001; 15(1): 9-13
17.Chen Shu-qing, Peter J Wedlund. Correlation between cytochrome P450 2D6 (CYP2D6) phenotype and genotype. Acta Pharmacol Sin. 1999; 20（7）：585-8
18.Shuqing Chen, Luhang Zhao, Xiaoping Zhao, Baiye Jin. Cytochrome P450 2C19 polymorphism and its relationship to cancer susceptibility. The 11th international conference on cytochrome P450. 1999.8.29-9.3 Sendai, Japan.
19.Chen Shu-qing, Sun Hong-ying，Zhao Lu-hang，Peter J Wedlund. Analysis of cytochrome P450 2D6 enzyme deficient allele CYP2D6T by allele-specific amplification. Progress in Biochemistry and Biophysics. 1999；26(1)：90-2
20.Shuqing Chen, S. Kumar, W-H Chou, J.S. Barrett and PJ Wedlund. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in random versus selected healthy subject populations. British Journal of Clinical Pharmacology. 1997;44:303-4
21.Shuqing Chen, Wen-Hwei Chou, Robert A. Blouin, Zhongping Mao, Laurie L. Humphries, Q. Craig Meek, John R. Neill, Walter L. Martin, Lon R. Hays and Peter J. Wedlund. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clinical Pharmacology and Therapeutics. 1996; 60: 522-34
22.Shuqing Chen, Victoria King, Peter Wedlund and L. Hays. Cytochrome P450-2D6 (CYP2D6): Simplified screening for the A and B alleles and deficient enzyme expression. Clinical Pharmacology and Therapeutics. 1995; 57(2): 150
23.Peter J. Wedlund, Shuqing Chen, J.R. Neill, Q.C. Meek and W.L. Martin. Cytochrome P450-2D6 (CYP2D6) alleles in depressed patients with adverse effects. Pharmaceutical Research 1995; 12(9): 380
